Sundaresan, Tilak K.
Dubash, Taronish D.
Zheng, Zongli
Bardia, Aditya
Wittner, Ben S.
Aceto, Nicola
Silva, Erin J.
Fox, Douglas B.
Liebers, Matthew
Kapur, Ravi
Iafrate, John
Toner, Mehmet
Maheswaran, Shyamala http://orcid.org/0000-0002-9356-1709
Haber, Daniel A.
Funding for this research was provided by:
National Institute of Health (2RO1CA129933, 2U01EB012493, 2U01EB012493, 2U01EB012493, 5U01EB012493, 5P41EB002503)
Susan G Komen Foundation (CCR15224703)
Howard Hughes Medical Institute
ESSCO Breast Cancer Research Fund
National Foundation for Cancer Research
MGH-Johnson & Johnson Center for Excellence in CTCs
Federal Share Research Career Development Award (K12CA087723)
Santander Cancer Research Fellowship
Human Frontiers Science Program
Swiss National Science Foundation
Swiss Foundation for Grants in Biology and Medicine
Article History
Received: 17 December 2020
Accepted: 24 May 2021
First Online: 8 June 2021
Declarations
:
: Massachusetts General Hospital (MGH) has applied for patents regarding the CTCi-Chip technology, CTC detection signatures, and Enrich-seq technology. M.T, S.M, and D.A.H are cofounders and have equity in Tell-Bio, which is not related to this work. J.I and Z.Z hold equity in ArcherDx. A.B holds Consultant/advisory board position: Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma, Taiho Pharm, Diiachi-Astra Zeneca, Eli Lilly, Sanofi, Puma, Foundation Medicine, and Phillips. Contracted research: Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Sanofi, and Biothernostics. All authors’ interests were reviewed and are managed by MGH and Partners HealthCare in accordance with their conflict of interest policies.
: Patients provided written informed consent to an Institutional Review Board approved blood collection protocol (DF/HCC 05-300).